@article{3061453,
    title = "New adamantane derivatives with sigma affinity and antiproliferative activity",
    author = "Riganas, S. and Papanastasiou, I. and Foscolos, G.B. and Tsotinis, A. and Dimas, K. and Kourafalos, V.N. and Eleutheriades, A. and Moutsos, V.I. and Khan, H. and Margarita, P. and Georgakopoulou, S. and Zaniou, A. and Theodoropoulou, M. and Mantelas, A. and Pondiki, S. and Vamvakides, A.",
    journal = "RSC Medicinal Chemistry",
    year = "2012",
    volume = "8",
    number = "4",
    pages = "569-586",
    doi = "10.2174/157340612801216201",
    keywords = "4 (1 adamantyl) 4,4 diarylbutylamine;  5 (1 adamantyl) 5,5 diarylpentylamine;  6 (1 adamantyl) 6,6 diarylhexylamine;  adamantane derivative;  alkene;  methanol;  sigma opiate receptor;  sodium channel;  unclassified drug, animal cell;  antineoplastic activity;  antiproliferative activity;  article;  binding affinity;  cancer cell;  drug binding;  human;  human cell;  in vitro study;  in vivo study;  mouse;  nonhuman;  priority journal, Adamantane;  Animals;  Antineoplastic Agents;  Binding Sites;  Cell Line, Tumor;  Cell Proliferation;  Drug Design;  Female;  Humans;  Male;  Mice;  Mice, SCID;  Neoplasms;  Receptors, sigma",
    abstract = "The synthesis of 4-(1-adamantyl)-4,4-diarylbutylamines 1, 5-(1-adamantyl)-5,5-diarylpentylamines 2 and 6-(1-adamantyl)-6,6- diarylhexylamines 3 is described and the σ1, σ2-receptors and sodium channels binding affinity of compounds 1 were investigated. The in vitro activity of compounds 1, 2 and 3 against main cancer cell lines is significant. One of the most active analogs, 1a, had an interesting in vivo anticancer profile against the ovarian cancer cell line IGROV-1, which was associated with an anagelsic activity against the neuropathic pain induced by the main anticancer drugs. © 2012 Bentham Science Publishers."
}